Treatment strategies to prevent relapse and encourage remission
- PMID: 18284275
Treatment strategies to prevent relapse and encourage remission
Abstract
Remission is a realistic goal for patients with schizophrenia, and, if sustained remission without relapse can be achieved, then patients may attain functional recovery. With each relapse, recovery can be slowed and the course of illness worsened. The risk of self-harm and harm to others increases with each psychotic episode. The chance of relapse is decreased if pharmacotherapy continues uninterrupted, and one strategy to ensure continuous treatment is using long-acting injectable antipsychotic medications. Achieving remission of schizophrenia is clinically meaningful because, besides symptom control, remission allows for improved vocational and social functioning. Functional recovery without relapse allows patients to return to work, sustain interpersonal relationships, and lead more productive lives. Therefore, achieving the goals of remission and recovery is in the best interest not only of patients with schizophrenia but also of society.
Similar articles
-
Relapse prevention and recovery in the treatment of schizophrenia.J Clin Psychiatry. 2006;67 Suppl 5:19-23. J Clin Psychiatry. 2006. PMID: 16822093
-
Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.Int Clin Psychopharmacol. 2008 Nov;23(6):325-31. doi: 10.1097/YIC.0b013e32830c2042. Int Clin Psychopharmacol. 2008. PMID: 18854720 Clinical Trial.
-
Improving patient outcomes in schizophrenia: achieving remission.J Psychopharmacol. 2006 Nov;20(6 Suppl):57-61. doi: 10.1177/1359786806071248. J Psychopharmacol. 2006. PMID: 17046987 Review.
-
An evidence-based strategy for remission in schizophrenia.J Clin Psychiatry. 2008;69 Suppl 3:25-30. J Clin Psychiatry. 2008. PMID: 18533759 Review.
-
Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study.Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1287-92. doi: 10.1016/j.pnpbp.2008.04.003. Epub 2008 Apr 9. Prog Neuropsychopharmacol Biol Psychiatry. 2008. PMID: 18502012
Cited by
-
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.CNS Drugs. 2020 Sep;34(9):961-972. doi: 10.1007/s40263-020-00745-1. CNS Drugs. 2020. PMID: 32621071 Free PMC article. Clinical Trial.
-
Real-world predictors of relapse in patients with schizophrenia and schizoaffective disorder in a large health system.Schizophrenia (Heidelb). 2024 Feb 29;10(1):28. doi: 10.1038/s41537-024-00448-2. Schizophrenia (Heidelb). 2024. PMID: 38424086 Free PMC article. Review.
-
Efficacy and Safety of TV-46000 and Second-Generation Long-Acting Injectable Antipsychotics for Schizophrenia: A Systematic Literature Review and Network Meta-Analysis of Randomized Controlled Trials.Adv Ther. 2025 Jul 16. doi: 10.1007/s12325-025-03274-9. Online ahead of print. Adv Ther. 2025. PMID: 40668497 Review.
-
TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia.Neuropsychiatr Dis Treat. 2024 Oct 9;20:1901-1917. doi: 10.2147/NDT.S459104. eCollection 2024. Neuropsychiatr Dis Treat. 2024. PMID: 39399879 Free PMC article.
-
Molecular Features Triggered by Antipsychotic Medication in Brain Cells.Adv Exp Med Biol. 2022;1400:65-73. doi: 10.1007/978-3-030-97182-3_5. Adv Exp Med Biol. 2022. PMID: 35930226
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical